Julie M. Cunningham
- Ovarian cancer diagnosis and treatment
- RNA modifications and cancer
- Cancer-related molecular mechanisms research
- BRCA gene mutations in cancer
- Cancer Genomics and Diagnostics
- Genetic factors in colorectal cancer
- Genetic Associations and Epidemiology
- Epigenetics and DNA Methylation
- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Nutrition, Genetics, and Disease
- Ferroptosis and cancer prognosis
- Chronic Lymphocytic Leukemia Research
- Cancer, Lipids, and Metabolism
- Cancer-related Molecular Pathways
- Lymphoma Diagnosis and Treatment
- DNA Repair Mechanisms
- Prostate Cancer Treatment and Research
- RNA Research and Splicing
- Pancreatic and Hepatic Oncology Research
- Glutathione Transferases and Polymorphisms
- Molecular Biology Techniques and Applications
- Colorectal Cancer Treatments and Studies
- Colorectal Cancer Screening and Detection
- Bioinformatics and Genomic Networks
Mayo Clinic
2015-2024
Mayo Clinic in Arizona
2015-2024
Nebraska Medical Center
2024
San Antonio Metropolitan Health District
2023
Ovarian Cancer Research Alliance
2009-2023
Cancer Australia
2010-2023
ID Genomics (United States)
2023
Mayo Clinic in Florida
2010-2022
WinnMed
2012-2022
University of Cambridge
2011-2017
Background Defective cellular transport processes can lead to aberrant accumulation of trace elements, iron, small molecules and hormones in the cell, which turn may promote formation reactive oxygen species, promoting DNA damage expression key regulatory cancer genes. As uncontrolled proliferation are hallmarks cancer, including epithelial ovarian (EOC), we hypothesized that inherited variation genes contributes EOC risk. Methods In total, samples were obtained from 14,525 case subjects...
PURPOSE: To compare microsatellite instability (MSI) testing with immunohistochemical (IHC) detection of hMLH1 and hMSH2 in colorectal cancer. PATIENTS AND METHODS: Colorectal cancers from 1,144 patients were assessed for DNA mismatch repair deficiency by two methods: MSI IHC gene products. High-frequency (MSI-H) was defined as more than 30% at least five markers; low-level (MSI-L) 1% to 29% loci unstable. RESULTS: Of tumors tested, 818 showed intact expression hMSH2. these, 680 stable...
To compare microsatellite instability (MSI) testing with immunohistochemical (IHC) detection of hMLH1 and hMSH2 in colorectal cancer.Colorectal cancers from 1,144 patients were assessed for DNA mismatch repair deficiency by two methods: MSI IHC gene products. High-frequency (MSI-H) was defined as more than 30% at least five markers; low-level (MSI-L) 1% to 29% loci unstable.Of tumors tested, 818 showed intact expression hMSH2. Of these, 680 stable (MSS), 27 MSI-H, 111 MSI-L. In all, 228...
Background:Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy, responsible for 13 000 deaths per year in United States. Risk prediction based on identifying germline mutations susceptibility genes could have a clinically significant impact reducing disease mortality.
Colon cancer arises from the accumulation of multiple genetic and epigenetic alterations to normal colonic tissue. microRNAs (miRNAs) are small, non-coding regulatory RNAs that post-transcriptionally regulate gene expression. Differential miRNA expression in versus tissue is a common event may be pivotal for tumor onset progression. To identify miRNAs differentially expressed tumors subtypes, we carried out highly sensitive profiling 735 on samples obtained statistically powerful set (n =...
Small intestine neuroendocrine tumors (SI-NETs) are the most common malignancy of small bowel. Several clinical trials target PI3K/Akt/mTOR signaling; however, it is unknown whether these or other genes genetically altered in tumors. To address underlying genetics, we analyzed 48 SI-NETs by massively parallel exome sequencing. We detected an average 0.1 somatic single nucleotide variants (SNVs) per 106 nucleotides (range, 0-0.59), mostly transitions (C>T and A>G), which suggests that stable...
The aim of this study was to estimate the contribution deleterious mutations in RAD51B, RAD51C, and RAD51D genes invasive epithelial ovarian cancer (EOC) population a screening trial individuals at high risk cancer.